Prognomix goal is to determine genomic profile of T2D patients with renal, cardiac and vascular disease to develop pre-symptomatic, predictive markers facilitating prevention of complications using the ADVANCE cohort.
- ADVANCE: is the largest clinical outcome trial in type 2 diabetics to date
- 11,140 patients and samples for DNA with informed consent
- Genetic sub-study led by P. Hamet and J. Tremblay
- High acceptance for informed consent for the genetic studies worldwide
- ADVANCE website
ADVANCE trial was performed in 20 countries indicated in red.